INCUBETA
13.1.2021 13:14:36 CET | Business Wire | Press release
Lars Lehne has been appointed Group CEO of Incubeta , the independent digital marketing services group. The former SYZYGY AG CEO will be taking over from the founder Alan Lipschitz, whose company Interface made the reverse acquisition of IncuBeta Holdings in 2011. Alan will be moving into the role of Chairperson of the Board of Directors of Incubeta.
Lars brings with him more than 30 years of industry experience. Prior to Incubeta Lars spent four years as Global CEO at SYZYGY, a publicly listed WPP company. Before that, he spent seven years at Google as Country Director Agency DACH, paving the way for the tech giant quadrupling revenues in Germany. He has also held various senior management positions in agencies including Maxus, GroupM, Carat and MEC.
In addition to his current role as new Group CEO of Incubeta, Lars is a member of the advisory board of Yext, and betterplace.org, a Berlin based NGO. He’s also an Angel Investor in CLAIMINI GmbH. As Group CEO, Lars will be leading company positioning and growth, including its operations in North America, driving the business strategy and further uniting the group across the globe.
Incubeta operates across 14 countries with offices in cities including London, New York, Los Angeles, Madrid, Sydney and Cape Town. In 2013 the highly successful Net Media Planet (NMPi) was acquired, which established significant growth for Incubeta as it boosted its advertising offerings. The subsequent acquisition in 2016 of forward-thinking marketing technology specialist DQ&A, extended the company’s geographical and product growth. This was followed by the acquisition of market leading creative specialist, Joystick, in 2018. Through these acquisitions, Incubeta offers clients a full suite of unrivalled services connecting Media, Technology and Creative.
In the last twelve months, Incubeta has launched several new innovative platforms. This has included the award-winning proprietary Seamless technology, including Seamless Search – which measures the incrementality of paid and organic SEO keywords – and Seamless Creative – which unifies media activity and creative assembly at scale. The company has also made a series of new appointments including senior hire John Cawdery as US CEO.
Alan Lipschitz, Founder and Chairperson of the Board, comments: “Having started a small South African business many years ago, I am so very proud of how far the company has come. By building a fantastic team around me and adding inspirational businesses from around the world, Incubeta has grown into a leading player in digital marketing services. The company is in a great place, yet I believe in order to accelerate pace and to meet the challenges of the future we need a different type of leader.
“I have the utmost faith Lars is the leader the company needs to take Incubeta forward. He has the expertise to bring the team further together, drive clear strategy, and build on the fantastic foundation I have been able to create with my wonderful team. So it is with great pride and pleasure that I hand the mantle of Chief Executive Officer of the Incubeta Group to Lars Lehne.”
Lars Lehne, Group CEO of Incubeta, comments: “I’m thrilled and honoured to be joining such a forward-thinking and innovative company. Incubeta has continued to grow during one of the most challenging years for the industry which is a testament to the quality and hard work of every team member across the globe. The company has flourished under Alan’s leadership and it's a great privilege that he’s trusting me to take his dream forward.
“As marketing continues to evolve at a rapid pace, it’s harder now than ever before for brands to connect with their customers. By integrating Media, Technology, and Creative in a seamless way Incubeta has developed the right services and products to help clients grow in a digital world. Incubeta puts the ownership of the customer experience back into the hands of its clients. I can’t wait to see what the next chapter for Incubeta looks like.”
-ENDS-
About Incubeta:
Incubeta is the union of three market leading specialists in Technology, Media, and Creative – DQ&A, NMPi, and Joystick respectively. By seamlessly integrating these three specialisms and rethinking the rules of marketing, Incubeta puts the ownership and control of the customer experience back in the hands of the advertiser, both brands and agencies.
As the largest and longest established GMP sales partner in EMEA and APAC, Incubeta has proven through working with top-tier brands that they are leading specialists in helping advertisers tackle complex projects such as in-housing, dynamic creative, data integration, real 1:1 marketing, and industry-specific segmentation modeling. Incubeta is primed to help advertisers deliver complex use cases across Google's Maturity Framework and Menu of Services.
Find out more at: incubeta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005451/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom